Consensus statement on the need for a specialist service for paediatric saliva control in neurodevelopmental disabilities.

Poor saliva control (sialorrhoea) represents a considerable burden to paediatric patients with neurodevelopmental disabilities, contributing significantly to both physical and psychological problems. Despite a significant proportion of paediatric patients with cerebral palsy (up to ~44%) and other neurological conditions suffering from sialorrhoea, no coordinated pathways for specialist clinics exist on a formal basis within the NHS.Several management strategies exist, ranging from conservative measures, enteral and transdermal medications, intraglandular botulinum toxin injections through to glandular and/or ductal surgery. Anti-cholinergic medications such as glycopyrronium bromide and transdermal hyoscine hydrobromide are effective but have frequent adverse effects, meaning they are unsuitable or contraindicated in some patients. More invasive procedures, such as intraglandular botulinum toxin injections and surgical interventions, are highly effective but require specialist clinics in a controlled setting.Therefore, a specialist interest group was set up to agree recommendations for equitable service delivery in line with current literature and recommendations from the National Institute for Health and Care Excellence and the American Academy for Cerebral Palsy and Developmental Medicine in order to address this current unmet need. The results of these recommendations are reported here.